Stuart A. Arbuckle - 09 Aug 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
09 Aug 2022
Net transactions value
-$1,411,189
Form type
4
Filing time
10 Aug 2022, 16:06:07 UTC
Previous filing
17 Jun 2022
Next filing
12 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $299,628 +1,926 +3% $155.57 66,686 09 Aug 2022 Direct
transaction VRTX Common Stock Sale $1,439,539 -4,790 -7.2% $300.53 61,896 09 Aug 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $271,278 -900 -1.5% $301.42 60,996 09 Aug 2022 Direct F1, F2, F4
holding VRTX Common Stock 140 09 Aug 2022 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1,926 -22% $0.000000 6,635 09 Aug 2022 Common Stock 1,926 $155.57 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.53 (range $300.00 to $300.84).
F4 Open market sales reported on this line occurred at a weighted average price of $301.42 (range $301.13 to $301.61).
F5 Fully vested.